<?xml version="1.0" encoding="UTF-8"?>
<p>The standard of care is now given by IFN-free combinations of DAAs. These regimens are very effective with SVR rates around 95%, irrespective of the viral characteristics of HCV. Tolerance to DAAs is very good- the frequencies of serious adverse events (AEs) are less than 10% and early discontinuation rates less than 5% [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>].
</p>
